SRPT Stock Approaching 52-Week High

Sarepta Therapeutics stock is trading -26.06% below its average target price of $167.9 after marking a 5.7% during today's afternoon session. Analysts are giving the Large-Cap Pharmaceutical company an average rating of buy and target prices ranging from $128.0 to $224.0 per share.

Sarepta Therapeutics has an average level of shares sold short, at 7.3% of its total share float. The stock's short ratio (also called days to cover) is 6.08. The company's insiders own 4.41% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.

Institutional investors own 88.6% of Sarepta Therapeutics's shares, which indicates they have a high level of confidence in the company.

Institutions Invested in Sarepta Therapeutics

Date Reported Holder Percentage Shares Value
2024-03-31 Vanguard Group Inc 9% 8,795,754 $1,091,992,872
2024-03-31 Blackrock Inc. 6% 5,960,370 $739,979,944
2024-03-31 Janus Henderson Group PLC 5% 4,891,417 $607,269,428
2024-03-31 Capital International Investors 5% 4,817,517 $598,094,742
2024-03-31 Avoro Capital Advisors LLC 5% 4,344,444 $539,362,729
2024-03-31 Wellington Management Group, LLP 3% 3,245,798 $402,965,826
2024-03-31 Farallon Capital Management LLC 3% 2,453,500 $304,602,028
2024-03-31 State Street Corporation 2% 2,122,491 $263,507,260
2024-03-31 Bank Of New York Mellon Corporation 2% 2,067,037 $256,622,646
2024-03-31 T. Rowe Price Investment Management, Inc. 2% 1,931,547 $239,801,562
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.